Phenotype of Peripheral NK Cells in Latent, Energetic, and Meningeal Tuberculosis
The mechanisms underlying the immunopathology of tuberculous meningitis (TBM), essentially the most extreme medical type of extrapulmonary tuberculosis (TB), will not be understood. It’s at present believed that the unfold of Mycobacterium tuberculosis (Mtb) from the lung is an early occasion that happens earlier than the institution of adaptive immunity. Therefore, a number of innate immune mechanisms could take part within the containment of Mtb an infection and stop extrapulmonary illness manifestations.
Pure killer (NK) cells take part in defensive processes that distinguish latent TB an infection (LTBI) from energetic pulmonary TB (PTB). Nevertheless, their function in TBM is unknown. Right here, we carried out a cross-sectional evaluation of circulating NK cellCID=”C008″ worth=”s” phenotype in a potential cohort of TBM sufferers (n = 10) utilizing circulation cytometry. Additionally, we addressed the responses of memory-like NK cell subpopulations to the contact with Mtb antigens in vitro. Lastly, we decided plasma ranges of soluble NKG2D receptor ligands in our cohort of TBM sufferers by enzyme-linked immunosorbent assay (ELISA). Our comparative teams consisted of people with LTBI (n = 11) and PTB (n = 27) sufferers.
We discovered that NK cells from TBM sufferers confirmed decrease absolute frequencies, greater CD69 expression, and poor growth of the CD45RO+ memory-like subpopulation upon Mtb publicity in vitro in comparison with LTBI people. As well as, a discount within the frequency of CD56brilliantCD16– NK cells characterised TBM sufferers however not LTBI or PTB topics. Our research expands on earlier studies in regards to the function of NK cells in TBM exhibiting a diminished frequency of cytokine-producing cells in comparison with LTBI and PTB.
LAT (Ab-255) Antibody |
|||
| MBS7130662-5x01mL | MyBiosource | 5x0.1mL | EUR 1200 |
LAT (Ab-255) Antibody |
|||
| MBS9402078-005mL | MyBiosource | 0.05mL | EUR 245 |
LAT (Ab-255) Antibody |
|||
| MBS9402078-01mL | MyBiosource | 0.1mL | EUR 305 |
LAT (Ab-255) Antibody |
|||
| MBS9402078-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
LAT (Ab-255) Antibody |
|||
| MBS858352-01mg | MyBiosource | 0.1mg | EUR 305 |
LAT (Ab-255) Antibody |
|||
| MBS858352-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
LAT (Ab-255) Antibody |
|||
| MBS858352-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
LAT (Ab-255) Antibody |
|||
| MBS858352-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
LAT (Ab-255) Antibody |
|||
| MBS858352-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
LAT (Ab-255) Conjugated Antibody |
|||
| C33313 | SAB | 100ul | EUR 476.4 |
LAT (Ab-255) Conjugated Antibody |
|||
| MBS9444320-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
LAT (Ab-255) Conjugated Antibody |
|||
| MBS9444320-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
LAT (Ab-255) Conjugated Antibody |
|||
| MBS9444320-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
LAT (Ab-255) Conjugated Antibody |
|||
| MBS9444320-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
LAT (Ab-255) Conjugated Antibody |
|||
| MBS9444320-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
Rabbit polyclonal LAT (Ab-255) antibody |
|||
| TA326210 | Origene Technologies GmbH | 100 µl | Ask for price |
Anti-JunD (Ab-255) Antibody |
|||
| A05609-2 | BosterBio | 100ul | EUR 360 |
|
Description: Boster Bio Anti-JunD (Ab-255) Antibody (Catalog # A05609-2). Tested in WB, IHC, IF applications. This antibody reacts with Human. |
|||
Anti-JunD (Ab-255) Antibody |
|||
| Y021028 | ABM | 100 µg | EUR 285 |
Anti-BDNF Antibody |
|||
| 56572 | Genovis AB | 100ug | EUR 466 |
Anti-BRD2 Antibody |
|||
| 13020 | Genovis AB | 100ug | EUR 518 |
Anti-HA Antibody |
|||
| 18850 | Genovis AB | 1mg | EUR 2415 |
Anti-HA Antibody |
|||
| 18850-01 | Genovis AB | 100ug | EUR 426 |
Anti-T7 Antibody |
|||
| 18862 | Genovis AB | 1mg | EUR 2415 |
Anti-T7 Antibody |
|||
| 18862-01 | Genovis AB | 100ug | EUR 426 |
Anti-T7 Antibody |
|||
| 18864 | Genovis AB | 1mg | EUR 2415 |
Anti-T7 Antibody |
|||
| 18864-01 | Genovis AB | 100ug | EUR 426 |
Anti-V5 Antibody |
|||
| 18868 | Genovis AB | 1mg | EUR 2415 |
Anti-V5 Antibody |
|||
| 18868-01 | Genovis AB | 100ug | EUR 426 |
Anti-V5 Antibody |
|||
| 18870 | Genovis AB | 1mg | EUR 2415 |
Anti-V5 Antibody |
|||
| 18870-01 | Genovis AB | 100ug | EUR 418 |
Anti-BACH1 Antibody |
|||
| 56246 | Genovis AB | 100ug | EUR 376 |
Anti-BRCA1 Antibody |
|||
| 3301 | Genovis AB | 100ug | EUR 503 |
Anti-BRCA1 Antibody |
|||
| 3302 | Genovis AB | 100ug | EUR 503 |
Anti-BNIP3 Antibody |
|||
| 2290 | Genovis AB | 100ug | EUR 487 |
Anti-Id3 Antibody |
|||
| 56209 | Genovis AB | 100ug | EUR 503 |
Anti-p84 Antibody |
|||
| 56248 | Genovis AB | 100ug | EUR 503 |
Anti-p53 Antibody |
|||
| 3339 | Genovis AB | 100ug | EUR 503 |
Anti-Tau Antibody |
|||
| 57011 | Genovis AB | 100ug | EUR 469 |
Anti-Tau Antibody |
|||
| 57012 | Genovis AB | 100ug | EUR 606 |
Anti-Tau Antibody |
|||
| 57013 | Genovis AB | 100ug | EUR 606 |
Anti-Ski Antibody |
|||
| 34021 | Genovis AB | 100ug | EUR 400 |
Anti-MLL.N Antibody |
|||
| 34041 | Genovis AB | 100ug | EUR 372 |
Anti-AF4 Antibody |
|||
| 34042 | Genovis AB | 100ug | EUR 384 |
Anti-ENL Antibody |
|||
| 34043 | Genovis AB | 100ug | EUR 392 |
Anti-CD2 Antibody |
|||
| 34053 | Genovis AB | 100ul | EUR 298 |
Anti-p53 Antibody |
|||
| 34065 | Genovis AB | 100ul | EUR 225 |
Anti-PSA Antibody |
|||
| 34069 | Genovis AB | 100ul | EUR 196 |
Anti-ASC Antibody |
|||
| 2287 | Genovis AB | 100ug | EUR 445 |
Anti-ATM Antibody |
|||
| 13012 | Genovis AB | 100ug | EUR 518 |
Anti-ATM Antibody |
|||
| 13014 | Genovis AB | 100ug | EUR 518 |
Anti-ATR Antibody |
|||
| 13016 | Genovis AB | 100ug | EUR 518 |
Anti-ATR Antibody |
|||
| 13018 | Genovis AB | 100ug | EUR 518 |
Anti-DNA Antibody |
|||
| 12403 | Genovis AB | 100ug | EUR 230 |
Anti-DNA Antibody |
|||
| 12403-100 | Genovis AB | 100ug | EUR 230 |
Anti-DNA Antibody |
|||
| 12403-1000 | Genovis AB | 1mg | EUR 903 |
Anti-DNA Antibody |
|||
| 12403-500 | Genovis AB | 500ug | EUR 460 |
Anti-DNA Antibody |
|||
| 12404 | Genovis AB | 100ug | EUR 230 |
Anti-DNA Antibody |
|||
| 12404-100 | Genovis AB | 100ug | EUR 230 |
Anti-DNA Antibody |
|||
| 12404-1000 | Genovis AB | 1mg | EUR 903 |
Anti-DNA Antibody |
|||
| 12404-500 | Genovis AB | 500ug | EUR 460 |
Anti-AU1 Antibody |
|||
| 18816-01 | Genovis AB | 100ug | EUR 426 |
Anti-AU1 Antibody |
|||
| 18818 | Genovis AB | 1mg | EUR 2415 |
Anti-AU1 Antibody |
|||
| 18818-01 | Genovis AB | 100ug | EUR 418 |
Anti-AU5 Antibody |
|||
| 18820-01 | Genovis AB | 100ug | EUR 418 |
Anti-AU5 Antibody |
|||
| 18822-01 | Genovis AB | 100ug | EUR 426 |
Anti-ECS Antibody |
|||
| 18830 | Genovis AB | 1mg | EUR 2415 |
Anti-ECS Antibody |
|||
| 18830-01 | Genovis AB | 100ug | EUR 426 |
Anti-ECS Antibody |
|||
| 18832-01 | Genovis AB | 100ug | EUR 426 |
Anti-KT3 Antibody |
|||
| 18854-01 | Genovis AB | 100ug | EUR 418 |
Anti-KT3 Antibody |
|||
| 18858-01 | Genovis AB | 100ug | EUR 418 |
Anti-DR5 Antibody |
|||
| 2421 | Genovis AB | 100ug | EUR 445 |
Anti-BRCAA1 Antibody |
|||
| 34022 | Genovis AB | 100ug | EUR 376 |
Anti-SMRT Antibody |
|||
| 56217 | Genovis AB | 100ug | EUR 503 |
Anti-MTBP Antibody |
|||
| 56222 | Genovis AB | 100ug | EUR 445 |
Anti-PERP Antibody |
|||
| 56225 | Genovis AB | 100ug | EUR 445 |
Anti-KLK4 Antibody |
|||
| 56237 | Genovis AB | 100ug | EUR 376 |
Anti-KLK5 Antibody |
|||
| 56238 | Genovis AB | 100ug | EUR 389 |
Anti-KLK9 Antibody |
|||
| 56239 | Genovis AB | 100ug | EUR 376 |
Anti-PRAC Antibody |
|||
| 56245 | Genovis AB | 100ug | EUR 376 |
Anti-XAB2 Antibody |
|||
| 56247 | Genovis AB | 100ug | EUR 376 |
Anti-Ago2 Antibody |
|||
| 70106 | Genovis AB | 200ug | EUR 497 |
Anti-Rab5 Antibody |
|||
| 56415 | Genovis AB | 100ug | EUR 315 |
Anti-CD74 Antibody |
|||
| 56451 | Genovis AB | 100ug | EUR 397 |
Anti-GIT1 Antibody |
|||
| 56537 | Genovis AB | 100ug | EUR 466 |
Anti-GFAP Antibody |
|||
| 56566 | Genovis AB | 100ug | EUR 466 |
Anti-DUX4 Antibody |
|||
| 57101 | Genovis AB | 100ug | EUR 390 |
Anti-Lead Antibody |
|||
| 60001 | Genovis AB | 0.5ml | EUR 420 |
Anti-PDRG Antibody |
|||
| 34012 | Genovis AB | 100ug | EUR 400 |
Anti-WWOX Antibody |
|||
| 34016 | Genovis AB | 100ug | EUR 400 |
Anti-DOG1 Antibody |
|||
| 34036 | Genovis AB | 100ug | EUR 372 |
Anti-HGAL Antibody |
|||
| 34044 | Genovis AB | 100ug | EUR 372 |
Anti-ROR2 Antibody |
|||
| 34045 | Genovis AB | 100ug | EUR 442 |
Anti-CD57 Antibody |
|||
| 34054 | Genovis AB | 100ul | EUR 209 |
Anti-PSAP Antibody |
|||
| 34070 | Genovis AB | 100ul | EUR 236 |
Anti-IDH1 Antibody |
|||
| 34074 | Genovis AB | 100ul | EUR 308 |
Anti-MLH1 Antibody |
|||
| 34077 | Genovis AB | 100ul | EUR 236 |
Anti-Atg5 Antibody |
|||
| 23004 | Genovis AB | 100ug | EUR 466 |
Anti-Atg5 Antibody |
|||
| 23005 | Genovis AB | 100ug | EUR 466 |
Anti-FBG4 Antibody |
|||
| 28105 | Genovis AB | 100ug | EUR 384 |
Anti-PAPK Antibody |
|||
| 28107 | Genovis AB | 100ug | EUR 384 |
Anti-KOS1 Antibody |
|||
| 28108 | Genovis AB | 100ug | EUR 384 |
Anti-SOX6 Antibody |
|||
| 28117 | Genovis AB | 100ug | EUR 384 |
Anti-FBG2 Antibody |
|||
| 28119 | Genovis AB | 100ug | EUR 397 |
Anti-FBG5 Antibody |
|||
| 28120 | Genovis AB | 100ug | EUR 384 |
Anti-F1Aa Antibody |
|||
| 2279 | Genovis AB | 100ug | EUR 445 |
Anti-RIP3 Antibody |
|||
| 2283 | Genovis AB | 100ug | EUR 445 |
Anti-HSF2 Antibody |
|||
| 11105 | Genovis AB | 100ug | EUR 400 |
Anti-Aha1 Antibody |
|||
| 11140 | Genovis AB | 100ug | EUR 346 |
Anti-MADD Antibody |
|||
| 1150 | Genovis AB | 100ug | EUR 445 |
Anti-ASK1 Antibody |
|||
| 1151 | Genovis AB | 100ug | EUR 445 |
Anti-KDEL Antibody |
|||
| 11076-200 | Genovis AB | 200ug | EUR 700 |
Anti-HDEL Antibody |
|||
| 11077 | Genovis AB | 100ug | EUR 479 |
Anti-CCR8 Antibody |
|||
| 2097 | Genovis AB | 100ug | EUR 445 |
Anti-IKKα Antibody |
|||
| 2115 | Genovis AB | 100ug | EUR 445 |
Anti-IKKα Antibody |
|||
| 2117 | Genovis AB | 100ug | EUR 445 |
Anti-SUR1 Antibody |
|||
| 11567 | Genovis AB | 100ug | EUR 466 |
Anti-mTOR Antibody |
|||
| 13034 | Genovis AB | 100ug | EUR 518 |
Anti-mTOR Antibody |
|||
| 13036 | Genovis AB | 100ug | EUR 518 |
Anti-HSF1 Antibody |
|||
| 12518 | Genovis AB | 100ug | EUR 397 |
Anti-NEI3 Antibody |
|||
| 12523 | Genovis AB | 100ug | EUR 384 |
Anti-Ku80 Antibody |
|||
| 12525 | Genovis AB | 100ug | EUR 384 |
Anti-Ku80 Antibody |
|||
| 12527 | Genovis AB | 100ug | EUR 384 |
Anti-MDC1 Antibody |
|||
| 12596 | Genovis AB | 100ug | EUR 457 |
Anti-IKKα Antibody |
|||
| 2025 | Genovis AB | 100ug | EUR 445 |
Anti-GPX7 Antibody |
|||
| 13911 | Genovis AB | 100ug | EUR 503 |
Anti-DcR2 Antibody |
|||
| 2419 | Genovis AB | 100ug | EUR 445 |
Anti-ARTS Antibody |
|||
| 11000 | Genovis AB | 100ug | EUR 445 |
Anti-Bassoon Antibody |
|||
| 56495 | Genovis AB | 100ug | EUR 435 |
Anti-NPFF1 Antibody |
|||
| 56110 | Genovis AB | 100ug | EUR 376 |
Anti-NPFF2 Antibody |
|||
| 56111 | Genovis AB | 100ug | EUR 376 |
Anti-cdc34 Antibody |
|||
| 56207 | Genovis AB | 100ug | EUR 503 |
Anti-Mre11 Antibody |
|||
| 56211 | Genovis AB | 100ug | EUR 503 |
Anti-Rad50 Antibody |
|||
| 56213 | Genovis AB | 100ug | EUR 503 |
Anti-Rad51 Antibody |
|||
| 56214 | Genovis AB | 100ug | EUR 503 |
Anti-RPA14 Antibody |
|||
| 56215 | Genovis AB | 100ug | EUR 503 |
Anti-RPA32 Antibody |
|||
| 56216 | Genovis AB | 100ug | EUR 503 |
Anti-RAD17 Antibody |
|||
| 56229 | Genovis AB | 100ug | EUR 376 |
Anti-MUC12 Antibody |
|||
| 56232 | Genovis AB | 100ug | EUR 376 |
Anti-MUC12 Antibody |
|||
| 56233 | Genovis AB | 100ug | EUR 376 |
Anti-KLK13 Antibody |
|||
| 56241 | Genovis AB | 100ug | EUR 376 |
Anti-KLK14 Antibody |
|||
| 56242 | Genovis AB | 100ug | EUR 376 |
Anti-KLK15 Antibody |
|||
| 56244 | Genovis AB | 100ug | EUR 376 |
Anti-LAMP1 Antibody |
|||
| 56270 | Genovis AB | 100ug | EUR 466 |
Anti-LAMP2 Antibody |
|||
| 56272 | Genovis AB | 100ug | EUR 448 |
Anti-DENTT Antibody |
|||
| 56316 | Genovis AB | 100ug | EUR 376 |
Anti-DREAM Antibody |
|||
| 70149 | Genovis AB | 100ug | EUR 376 |
Anti-PSD95 Antibody |
|||
| 56452 | Genovis AB | 100ug | EUR 457 |
Anti-PSD95 Antibody |
|||
| 56457 | Genovis AB | 100ug | EUR 457 |
Anti-EAAC1 Antibody |
|||
| 56520 | Genovis AB | 100ug | EUR 466 |
Anti-PINK1 Antibody |
|||
| 56548 | Genovis AB | 100ug | EUR 466 |
Anti-VDAC1 Antibody |
|||
| 56564 | Genovis AB | 100ug | EUR 466 |
Anti-PSDR1 Antibody |
|||
| 34007 | Genovis AB | 100ug | EUR 376 |
Anti-SHPRH Antibody |
|||
| 34009 | Genovis AB | 100ug | EUR 400 |
Anti-NORE1 Antibody |
|||
| 34010 | Genovis AB | 100ug | EUR 400 |
Anti-EAP11 Antibody |
|||
| 34011 | Genovis AB | 100ug | EUR 400 |
Anti-TERE1 Antibody |
|||
| 34031 | Genovis AB | 100ug | EUR 278 |
Anti-Atg2A Antibody |
|||
| 23001 | Genovis AB | 100ug | EUR 466 |
Anti-Atg4C Antibody |
|||
| 23002 | Genovis AB | 100ug | EUR 466 |
Anti-Atg4D Antibody |
|||
| 23003 | Genovis AB | 100ug | EUR 466 |
Anti-Atg12 Antibody |
|||
| 23007 | Genovis AB | 100ug | EUR 466 |
An oncolytic virus expressing IL-15/IL-15Rα mixed with off-the-shelf EGFR-CAR NK cells targets glioblastoma
Interleukin (IL)-15 is a pleiotropic cytokine with a number of roles that enhance immune responses to tumor cells. Oncolytic viruses (OV) particularly lyse tumors and activate immune responses. Systemic administration of IL-15 or its advanced with the IL-15Rα and chimeric antigen receptor (CAR) pure killer (NK) cells are at present being examined within the clinic. Right here we generated a herpes simplex 1-based OV expressing human IL-15/IL-15Rα sushi area fusion protein (named OV-IL15C), in addition to off-the-shelf EGFR-CAR NK cells, and studied their monotherapy and mixture efficacy in vitro and in a number of glioblastoma (GBM) mouse fashions. In vitro, soluble IL-15/IL-15Rα advanced was secreted from OV-IL15C-infected GBM cells, which promoted GBM cytotoxicity and improved survival of NK and CD8+ T cells.
Frozen, available off-the-shelf EGFR-CAR NK cells confirmed enhanced killing of tumor cells in comparison with empty vector-transduced NK cells. In vivo, OV-IL15C considerably inhibited tumor development and extended survival of GBM-bearing mice within the presence of CD8+ T cells in comparison with parental OV. OV-IL15C plus EGFR-CAR NK cells synergistically suppressed tumor development and considerably improved survival in comparison with both monotherapy, correlating with elevated intracranial infiltration and activation of NK and CD8+ T cells and elevated persistence of CAR NK cells in an immunocompetent mannequin. Collectively, OV-IL15C and off-the-shelf EGFR-CAR NK cells characterize promising therapeutic methods for GBM remedy to enhance the medical administration of this devastating illness.
IL-21 and IFNα remedy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques
Not like HIV an infection, which progresses to AIDS absent suppressive anti-retroviral remedy, nonpathogenic infections in pure hosts, such African inexperienced monkeys, are characterised by a scarcity of intestine microbial translocation and strong secondary lymphoid pure killer cell responses leading to an absence of continual irritation and restricted SIV dissemination in lymph node B-cell follicles. Right here we report, utilizing the pathogenic mannequin of antiretroviral therapy-treated, SIV-infected rhesus macaques that sequential interleukin-21 and interferon alpha remedy generate terminally differentiated blood pure killer cells (NKG2a/clowCD16+) with potent human leukocyte antigen-E-restricted exercise in response to SIV envelope peptides. That is in distinction to regulate macaques, the place much less differentiated, interferon gamma-producing pure killer cells predominate.
The frequency and exercise of terminally differentiated NKG2a/clowCD16+ pure killer cells correlates with a discount of replication-competent SIV in lymph node throughout antiretroviral remedy and time to viral rebound following analytical remedy interruption. These information reveal that African inexperienced monkey-like pure killer cell differentiation profiles will be rescued in rhesus macaques to advertise viral clearance in tissues.
Single-cell profiling identifies impaired adaptive NK cells expanded after HCMV reactivation in haploidentical-HSCT
Haploidentical hematopoietic stem cell transplantation (h-HSCT) represents an environment friendly healing strategy for sufferers affected by hematologic malignancies through which the diminished depth conditioning induces a state of immunologic tolerance between donor and recipient. Nevertheless, opportunistic viral infections tremendously have an effect on h-HSCT medical outcomes. Pure Killer (NK) cells are the primary lymphocytes recovering after transplant and supply a immediate protection in opposition to human Cytomegalovirus (HCMV) an infection/reactivation. By endeavor a longitudinal single cell computational profiling of multiparametric circulation cytometry, we present that HCMV accelerates NK cell immune-reconstitution along with the growth of CD158b1b2jpos/NKG2Aneg/NKG2Cpos/NKp30low NK cells.
The frequency of this subset correlates with HCMV viremia, additional will increase in recipients experiencing a number of episodes of viral reactivations and persists for months after the an infection. The transcriptional profile of FACS-sorted CD158b1b2jpos NK cells confirmed the flexibility of HCMV to de-regulate NKG2C, NKG2A and NKp30 gene expression, thus inducing the growth of NK cells with adaptive traits. These NK cells are characterised by the down-modulation of a number of gene pathways related to cell migration, cell-cycle, effector-functions and by a state of metabolic/mobile exhaustion. This profile displays the useful impairments of adaptive NK cells to supply IFN-γ, a phenomenon additionally as a result of viral-induced expression of LAG-Three and PD-1 checkpoint-inhibitors.
Variations within the Expression of KIR, ILT Inhibitory Receptors, and VEGF Manufacturing within the Induced Decidual NK Cell Cultures of Fertile and RPL Girls
Outcomes: KIR2DL1 and ILT-2 expression on idNK cells was greater in wholesome ladies than in RPL sufferers. Sildenafil enhanced NKG2A expression in RPL sufferers. VEGF focus was greater in fertile lady idNK cell cultures. idNK cells have been extra delicate for necrosis in RPL than in fertile ladies. SC didn’t affect VEGF manufacturing or idNK cell apoptosis.
Conclusions: A mixture of hypoxia, IL-15, and AZA promotes the conversion of pbNK into idNK cells CD56+CD16–-expressing KIR receptors and produces VEGF. Alterations in KIR2DL1 and ILT-2 expression in addition to impaired VEGF manufacturing have been related to RPL. SC impacts NKG2A expression on RPL idNK cells. SC had no impact on VEGF launch or idNK cell apoptosis.
MS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV734271 | ABM | 1.0 ug DNA | Ask for price |
NA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV735849 | ABM | 1.0 ug DNA | Ask for price |
NM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV736287 | ABM | 1.0 ug DNA | Ask for price |
IV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730179 | ABM | 1.0 ug DNA | Ask for price |
P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV739461 | ABM | 1.0 ug DNA | Ask for price |
NP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814303 | ABM | 1.0 ug DNA | EUR 540 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV701983 | ABM | 1.0 ug DNA | EUR 540 |
C8A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702505 | ABM | 1.0 ug DNA | EUR 540 |
SLN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702973 | ABM | 1.0 ug DNA | EUR 540 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703483 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703699 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703819 | ABM | 1.0 ug DNA | EUR 540 |
FGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704107 | ABM | 1.0 ug DNA | EUR 540 |
NNT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704257 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV705295 | ABM | 1.0 ug DNA | EUR 540 |
WSN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV755991 | ABM | 1.0 ug DNA | Ask for price |
WT2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV755997 | ABM | 1.0 ug DNA | Ask for price |
WTS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756003 | ABM | 1.0 ug DNA | Ask for price |
WWS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756021 | ABM | 1.0 ug DNA | Ask for price |
XCE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756045 | ABM | 1.0 ug DNA | Ask for price |
XGR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756051 | ABM | 1.0 ug DNA | Ask for price |
XIC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756063 | ABM | 1.0 ug DNA | Ask for price |
TYS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV754917 | ABM | 1.0 ug DNA | Ask for price |
VCF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV755577 | ABM | 1.0 ug DNA | Ask for price |
VDI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV755613 | ABM | 1.0 ug DNA | Ask for price |
RP6 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747189 | ABM | 1.0 ug DNA | Ask for price |
RSS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747633 | ABM | 1.0 ug DNA | Ask for price |
S11 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747687 | ABM | 1.0 ug DNA | Ask for price |
S12 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747693 | ABM | 1.0 ug DNA | Ask for price |
SDU Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV748131 | ABM | 1.0 ug DNA | Ask for price |
SEA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV748137 | ABM | 1.0 ug DNA | Ask for price |
PRD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV741573 | ABM | 1.0 ug DNA | Ask for price |
PRS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV741753 | ABM | 1.0 ug DNA | Ask for price |
TDD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV750297 | ABM | 1.0 ug DNA | Ask for price |
THM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV750405 | ABM | 1.0 ug DNA | Ask for price |
TOC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV750681 | ABM | 1.0 ug DNA | Ask for price |
ST2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV749655 | ABM | 1.0 ug DNA | EUR 686.4 |
ST3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV749661 | ABM | 1.0 ug DNA | Ask for price |
ST4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV749673 | ABM | 1.0 ug DNA | Ask for price |
ST8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV749691 | ABM | 1.0 ug DNA | Ask for price |
CCT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720669 | ABM | 1.0 ug DNA | Ask for price |
CCV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720723 | ABM | 1.0 ug DNA | Ask for price |
CHR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721173 | ABM | 1.0 ug DNA | Ask for price |
CMM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721407 | ABM | 1.0 ug DNA | Ask for price |
CNC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721455 | ABM | 1.0 ug DNA | Ask for price |
COP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721599 | ABM | 1.0 ug DNA | Ask for price |
CRG Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721785 | ABM | 1.0 ug DNA | Ask for price |
CRS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721797 | ABM | 1.0 ug DNA | Ask for price |
CSE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721839 | ABM | 1.0 ug DNA | Ask for price |
CTD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV721923 | ABM | 1.0 ug DNA | Ask for price |
DCE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV722337 | ABM | 1.0 ug DNA | Ask for price |
DDU Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV722361 | ABM | 1.0 ug DNA | Ask for price |
EVL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709843 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710251 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710257 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710263 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710269 | ABM | 1.0 ug DNA | EUR 379.2 |
FTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710275 | ABM | 1.0 ug DNA | EUR 379.2 |
FUZ Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710293 | ABM | 1.0 ug DNA | EUR 379.2 |
GIP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710407 | ABM | 1.0 ug DNA | EUR 379.2 |
GRN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710665 | ABM | 1.0 ug DNA | EUR 379.2 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710833 | ABM | 1.0 ug DNA | EUR 379.2 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV710839 | ABM | 1.0 ug DNA | EUR 379.2 |
HYI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV711145 | ABM | 1.0 ug DNA | EUR 379.2 |
JTB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV711559 | ABM | 1.0 ug DNA | EUR 379.2 |
LBH Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV711901 | ABM | 1.0 ug DNA | EUR 379.2 |
LTF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712075 | ABM | 1.0 ug DNA | EUR 379.2 |
LUM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712087 | ABM | 1.0 ug DNA | EUR 379.2 |
LXN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712093 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712171 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712177 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712183 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712189 | ABM | 1.0 ug DNA | EUR 379.2 |
MPI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712369 | ABM | 1.0 ug DNA | EUR 379.2 |
NF2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712735 | ABM | 1.0 ug DNA | EUR 379.2 |
NMI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712777 | ABM | 1.0 ug DNA | EUR 379.2 |
BID Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707851 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707875 | ABM | 1.0 ug DNA | EUR 379.2 |
BMF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707881 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708259 | ABM | 1.0 ug DNA | EUR 379.2 |
CA8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708265 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708343 | ABM | 1.0 ug DNA | EUR 379.2 |
CBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708349 | ABM | 1.0 ug DNA | EUR 379.2 |
CGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708673 | ABM | 1.0 ug DNA | EUR 379.2 |
CKB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708757 | ABM | 1.0 ug DNA | EUR 379.2 |
CRK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708991 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708997 | ABM | 1.0 ug DNA | EUR 379.2 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709003 | ABM | 1.0 ug DNA | EUR 379.2 |
DTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709471 | ABM | 1.0 ug DNA | EUR 379.2 |
OAT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV712987 | ABM | 1.0 ug DNA | EUR 379.2 |